- Home
- ACM vs BMRN Comparison
ACM vs BMRN Comparison
Compare ACM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | BMRN |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.4B |
| IPO Year | 2007 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ACM | BMRN |
|---|---|---|
| Price | $72.71 | $54.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $131.30 | $88.22 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 42.71 | N/A |
| EPS | ★ 1.95 | 0.54 |
| Revenue | ★ $16,139,622,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | $6.06 | $12.23 |
| P/E Ratio | ★ $37.13 | $101.22 |
| Revenue Growth | 0.21 | ★ 17.62 |
| 52 Week Low | $67.64 | $49.26 |
| 52 Week High | $135.52 | $66.28 |
Technical Indicators
Market Signals| Indicator | ACM | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 52.78 |
| Support Level | $67.64 | $51.74 |
| Resistance Level | $73.56 | $56.91 |
| Average True Range (ATR) | 2.52 | 1.86 |
| MACD | 0.45 | 0.37 |
| Stochastic Oscillator | 81.59 | 65.69 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets, including water, transportation, and environment. Based in Dallas, Aecom employs 51,000 people. The company generated $16.1 billion in sales in fiscal 2025.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.